Oryzon Genomics S.A.
ORYZF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 96.5% | – | 95.9% |
| EBITDA | -$0 | $0 | -$0 | $0 |
| % Margin | – | 7% | – | 72.2% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | – | -0.7% | – | -16.4% |
| EPS Diluted | 0.01 | -0 | -0.026 | -0.018 |
| % Growth | 2,600% | 98.5% | -49.7% | – |
| Operating Cash Flow | – | $0 | $0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | $0 | $0 |